MYC Expression and Metabolic Redox Changes in Cancer Cells

A Synergy Able to Induce Chemoresistance

Barbara Marengo, Ombretta Garbarino, Andrea Speciale, Lorenzo Monteleone, Nicola Traverso, Cinzia Domenicotti

Research output: Contribution to journalReview article

Abstract

Chemoresistance is due to multiple factors including the induction of a metabolic adaptation of tumor cells. In fact, in these cells, stress conditions induced by therapies stimulate a metabolic reprogramming which involves the strengthening of various pathways such as glycolysis, glutaminolysis and the pentose phosphate pathway. This metabolic reprogramming is the result of a complex network of mechanisms that, through the activation of oncogenes (i.e., MYC, HIF1, and PI3K) or the downregulation of tumor suppressors (i.e., TP53), induces an increased expression of glucose and/or glutamine transporters and of glycolytic enzymes. Therefore, in order to overcome chemoresistance, it is necessary to develop combined therapies which are able to selectively and simultaneously act on the multiple molecular targets responsible for this adaptation. This review is focused on highlighting the role of MYC in modulating the epigenetic redox changes which are crucial in the acquisition of therapy resistance.

Original languageEnglish
Article number7346492
JournalOxidative Medicine and Cellular Longevity
Volume2019
DOIs
Publication statusPublished - Jan 1 2019
Externally publishedYes

Fingerprint

Oxidation-Reduction
Tumors
Cells
Pentoses
Complex networks
Glutamine
Phosphatidylinositol 3-Kinases
Pentose Phosphate Pathway
Neoplasms
Chemical activation
Phosphates
Glycolysis
Oncogenes
Epigenomics
Glucose
Enzymes
Therapeutics
Down-Regulation

ASJC Scopus subject areas

  • Biochemistry
  • Ageing
  • Cell Biology

Cite this

Marengo, B., Garbarino, O., Speciale, A., Monteleone, L., Traverso, N., & Domenicotti, C. (2019). MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance. Oxidative Medicine and Cellular Longevity, 2019, [7346492]. https://doi.org/10.1155/2019/7346492

MYC Expression and Metabolic Redox Changes in Cancer Cells : A Synergy Able to Induce Chemoresistance. / Marengo, Barbara; Garbarino, Ombretta; Speciale, Andrea; Monteleone, Lorenzo; Traverso, Nicola; Domenicotti, Cinzia.

In: Oxidative Medicine and Cellular Longevity, Vol. 2019, 7346492, 01.01.2019.

Research output: Contribution to journalReview article

Marengo, Barbara ; Garbarino, Ombretta ; Speciale, Andrea ; Monteleone, Lorenzo ; Traverso, Nicola ; Domenicotti, Cinzia. / MYC Expression and Metabolic Redox Changes in Cancer Cells : A Synergy Able to Induce Chemoresistance. In: Oxidative Medicine and Cellular Longevity. 2019 ; Vol. 2019.
@article{9323179bdacf48e4a87e05f38e5b4728,
title = "MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance",
abstract = "Chemoresistance is due to multiple factors including the induction of a metabolic adaptation of tumor cells. In fact, in these cells, stress conditions induced by therapies stimulate a metabolic reprogramming which involves the strengthening of various pathways such as glycolysis, glutaminolysis and the pentose phosphate pathway. This metabolic reprogramming is the result of a complex network of mechanisms that, through the activation of oncogenes (i.e., MYC, HIF1, and PI3K) or the downregulation of tumor suppressors (i.e., TP53), induces an increased expression of glucose and/or glutamine transporters and of glycolytic enzymes. Therefore, in order to overcome chemoresistance, it is necessary to develop combined therapies which are able to selectively and simultaneously act on the multiple molecular targets responsible for this adaptation. This review is focused on highlighting the role of MYC in modulating the epigenetic redox changes which are crucial in the acquisition of therapy resistance.",
author = "Barbara Marengo and Ombretta Garbarino and Andrea Speciale and Lorenzo Monteleone and Nicola Traverso and Cinzia Domenicotti",
year = "2019",
month = "1",
day = "1",
doi = "10.1155/2019/7346492",
language = "English",
volume = "2019",
journal = "Oxidative Medicine and Cellular Longevity",
issn = "1942-0900",
publisher = "Hindawi Limited",

}

TY - JOUR

T1 - MYC Expression and Metabolic Redox Changes in Cancer Cells

T2 - A Synergy Able to Induce Chemoresistance

AU - Marengo, Barbara

AU - Garbarino, Ombretta

AU - Speciale, Andrea

AU - Monteleone, Lorenzo

AU - Traverso, Nicola

AU - Domenicotti, Cinzia

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chemoresistance is due to multiple factors including the induction of a metabolic adaptation of tumor cells. In fact, in these cells, stress conditions induced by therapies stimulate a metabolic reprogramming which involves the strengthening of various pathways such as glycolysis, glutaminolysis and the pentose phosphate pathway. This metabolic reprogramming is the result of a complex network of mechanisms that, through the activation of oncogenes (i.e., MYC, HIF1, and PI3K) or the downregulation of tumor suppressors (i.e., TP53), induces an increased expression of glucose and/or glutamine transporters and of glycolytic enzymes. Therefore, in order to overcome chemoresistance, it is necessary to develop combined therapies which are able to selectively and simultaneously act on the multiple molecular targets responsible for this adaptation. This review is focused on highlighting the role of MYC in modulating the epigenetic redox changes which are crucial in the acquisition of therapy resistance.

AB - Chemoresistance is due to multiple factors including the induction of a metabolic adaptation of tumor cells. In fact, in these cells, stress conditions induced by therapies stimulate a metabolic reprogramming which involves the strengthening of various pathways such as glycolysis, glutaminolysis and the pentose phosphate pathway. This metabolic reprogramming is the result of a complex network of mechanisms that, through the activation of oncogenes (i.e., MYC, HIF1, and PI3K) or the downregulation of tumor suppressors (i.e., TP53), induces an increased expression of glucose and/or glutamine transporters and of glycolytic enzymes. Therefore, in order to overcome chemoresistance, it is necessary to develop combined therapies which are able to selectively and simultaneously act on the multiple molecular targets responsible for this adaptation. This review is focused on highlighting the role of MYC in modulating the epigenetic redox changes which are crucial in the acquisition of therapy resistance.

UR - http://www.scopus.com/inward/record.url?scp=85070513836&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070513836&partnerID=8YFLogxK

U2 - 10.1155/2019/7346492

DO - 10.1155/2019/7346492

M3 - Review article

VL - 2019

JO - Oxidative Medicine and Cellular Longevity

JF - Oxidative Medicine and Cellular Longevity

SN - 1942-0900

M1 - 7346492

ER -